Evaluation of genotoxic potential of pemetrexed by using in vitro alkaline comet assay

Yıl 2017, Cilt: 21 Sayı: 3, 544 - 550, 20.06.2017

Hayal Çobanoğlu Münevver Coşkun Mahmut Coşkun Akın Çayır

https://doi.org/10.12991/marupj.318635

Öz

Pemetrexed is a chemotherapeutic drug, approved for the

treatment of mesothelioma and non–small cell lung cancer

and variety of neoplasm. Chemotherapeutic drugs don’t target

only cancer cells in treatment. During treatment these drugs

encounter with normal cells as well. Therefore, in this in vitro

study, it was aimed to investigate the whether genotoxic effect

or not of Pemetrexed on normal leukocytes. In vitro alkaline

comet assay was used in this study. Leukocytes from human

peripheral blood samples from two volunteer donors were

used in the study. In the present study, leukocytes were treated

with four different concentrations (25, 50, 75, and 100 μg/ml)

of the drug for 1 hour. At concentration of 75 μg/ml and 100

μg/ml, there were statistically significant increases in DNA

damage compared to the negative control (p˂0.05, and p˂0.01

respectively). The obtained result shows that Pemetrexed may

have genotoxic potential on normal leucocytes.

Anahtar Kelimeler

Genotoxicity; comet assay; pemetrexed

Pemetrekset’in in vitro Alkali Tek Hücre Jel Elektroforez Yöntemi ile Genotoksik Potansiyelinin Değerlendirilmesi

Öz

Pemetrekset, mezotelyoma, küçük hücreli olmayan akciğer

kanseri ve pek çok neoplazmın tedavisinde kullanılan

kemoterapötik bir ilaçtır. Kemoterapötik ilaçlar tedavide

sadece kanser hücrelerini hedeflemezler. Tedavi süresince

normal hücrelerde bu ilaçlarla karşılaşırlar. Buradan yola

çıkılarak planlanan bu çalışmada, pemetrekset’in in vitro

koşullarda nomal lökositler üzerine genotoksik etkisinin

olup olmadığının ortaya konulması amaçlandı. Çalışmada,

genotoksisite çalışmalarında hızlı ve güvenilir sonuçlar vermesi

dolayısıyla sıklıkla kullanılan bir yöntem olan alkali tek hücre

jel elektroforez yöntemi kullanıldı. İki gönüllü donörden alınan

insan periferal kan örneklerinden elde edilen lökositler, ilacın

dört farklı konsantrasyonu (25, 50, 75 ve 100μg/mL) ile 1 saat

muamele edildi. DNA hasarı bakımından 75μg/mL (p˂0,05) ve

100μg/ml’de (p˂0,01) negatif kontrole göre istatistiksel olarak

anlamlı bir artış tespit edildi. Bu bulgu, pemetrekset’in normal

lökositler üzerine genotoksik potansiyelinin olabileceğini

göstermektedir.

Anahtar Kelimeler

Genotoksisite; tek hücre jel elektroforez yöntemi; pemetrekset

Kaynakça

• 1. Dalkic E, Wang X, Wright N, Chan C. Cancer-Drug Associations: A complex system. PLoS ONE 2010; 5: 1-15.
• 2. T.C Türkiye Halk Sağlığı Kurumu. Türkiye kanser istatistikleri http://kanser.gov.tr/Dosya/2017Haberler/2014-RAPOR.pdf (Erişim tarihi: 07 Şubat 2017).
• 3. Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı. Kanser istatistikleri http://kanser.gov.tr/ Dosya/2017Haberler/2017_4_subat.pdf (Erişim Tarihi: 07 Şubat 2017).
• 4. Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı. Kanser Tedavisi http://kanser.gov.tr/kanser/kanser-tedavisi/38- kanser-tedavisi.html (Erişim tarihi: 07 Şubat 2017).
• 5. Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E. Phase II studyof pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer 2001; 92: 595-600.
• 6. Istifli ES, Topaktas M. Genotoxicity of pemetrexed in human peripheral blood lymphocytes. Cytotechnology 2013; 65: 621- 8.
• 7. Eldin NE, Elnahas HM, Mahdy MAE, Ishida T. Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma. Biol Pharm Bull 2015; 38: 461-9.
• 8. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-17.
• 9. Choudhury RC, Ghosh SK, Palo AK. Potential transmission of the cytogenetic toxic effects of methotrexate in the male germline cells of swiss mice. Environ Toxicol Pharmacol 2001; 10: 81-8.
• 10. Rojas E, Valverde M, Lopez MC, Naufal I , Sanchez I, Bizarro P, Lopez I, Fortoul TI, Wegman PO. Evaluation of DNA damage in exfoliated tear duct epithelial cells from individuals exposed to air pollution assessed by single cell gel electrophoresis assay. Mutat Res 2000; 468: 11-7.
• 11. Dusinska M, Collins AR. The comet in human biomonitoring: Gene–environment interactions. Mutagenesis 2008; 23: 191- 205.
• 12. Karlsson HL, Bucchianico SD, Collins AR, Dusinska M. Can the comet assay be used reliably to detect nanoparticleinduced genotoxicity? Environ Mol Mutagen 2015; 56: 82-96.
• 13. Villarini M, Moretti M, Pasquini R, Sforzolini GS, Fatigoni C, Marcarelli M, Monarca S, Rodrıgue AV. In vitro genotoxic effects of the insecticide deltamethrin in human peripheral blood leukocytes: DNA damage (comet) in relation to the induction of sister-chromatid exchanges and micronuclei. Toxicol 1998; 130: 129-39.
• 14. Vandghanooni S, Eskandani M. Comet: a method to evaluate genotoxicity of nano-drug delivery system. BioImpacts 2011; 1: 87-97.
• 15. Nunes APM, Machado SCF, Nunes RM, Danta FJS, De Mattos JCP, de-Arau jo AC. Analysis of genotoxic potentiality of stevioside by comet. Food Chem Toxicol 2007; 45: 662-6.
• 16. Rozgaj R, Kasuba V, Brozovic G , Jazbec A. Genotoxic effects of anaesthetics in operating theatre personnel evaluated by the comet and micronucleus test. Int J Hyg Environ Health 2009; 212: 11-7.
• 17. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. Single cell gel/comet: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-21.
• 18. Szeto YT, Benzie IFF, Collins AR, Choi SW, Cheng CY, Yow CMN, Tse MMY. A buccal cell model comet assay: Development and evaluation for human biomonitoring and nutritional studies. Mutat Res 2005; 578: 371-81.
• 19. Wang Y, Zhao R, Goldman ID. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003; 65: 1163-70.
• 20. Giovannetti E, Mey V, Danesi R, Mosca I, Tacca MD. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10: 2936-43.
• 21. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Tacca MD, Danesi R. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non–small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-8.
• 22. Li T, Ling YH, Goldman D, Perez-Soler R. Scheduledependent cytotoxic synergism of pemetrexed and erlotinib in human nonsmall cell lung cancer cells. Clin Cancer Res 2007; 13: 3413-22.
• 23. Buqué A, Muhialdin JS, Muñoz A, Calvo B, Carrera S, Aresti U, Sancho A, Rubio I, Vivanco GL. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. Mol Cancer 2012; 11: 2-15.
• 24. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH, Sheu GT, Hsu SL. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/ p53-dependent and -independent signaling pathways. Mol Carcinog 2013; 52: 183-94.
• 25. Dhawan A, Bajpayee M, Pandey AK, Parmar D. Protocol for the single cell gel electrophoresis/comet for rapid genotoxicity assessment. http://www.cometassayindia.org/protocol%20 for%20comet%20assay.pdf. Erişim tarihi : 20 February 2017. 26. Collins AR. The comet for DNA damage and repair. Mol Biotechnol 2004; 26: 249-61.
• 27. Shahin AA, Ismail MM, Saleh AM, Moustafa HA, Aboul-Ella AA, Gabr HM. Protective effect of folinic acid on low-dose methotrexate genotoxicity. Z Rheumatol 2001; 60: 63-8.
• 28. Padmanabhan S, Tripathi DN, Vikram A, Ramarao P, Jena GB. Methotrexate-induced cytotoxicity and genotoxicity in germ cells of mice: Intervention of folic and folinic acid. Mutat Res 2009; 673: 43-52.
• 29. Kalweit S, Vasudey V, Obe G. Liquid-holding experiments with human lymphocytes; III experiments with G0 and G1 cells. Mutat Res 1988; 207: 41-4.
• 30. Collins AR, Dobson VR, Dusinska M, Kennedy G, Stetina R. The comet assay: What can it really tell us?. Mutat Res 1997; 375: 183-93.
• 31. Comet Assay Interest Group. http://cometassay.com/index_ files/Page345.htm (Erişim tarihi 15 Şubat 2017).
• 32. Kastan MB. DNA damage responses: mechanisms and roles in human disease. Mol Cancer Res 2008; 6: 517-24.
• 33. McKenna DJ, McKeown SR, McKelvey-Martin VJ. Potential use of the comet in the clinical management of cancer. Mutagenesis 2008; 23: 183-90.